NCT Number: NCT05714722
Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma
Background: Colorectal neuroendocrine carcinomas (CRNECs) are highly aggressive tumours with poor prognosis and low incidence. To date, the genomic landscape and molecular pathway alterations have not been elucidated.
Methods: Tissue sections and clinical information were collected as an in-house cohort (2010-2020). Large-scale genomic and genetic panels were applied to identify the genomic and genetic alterations of CRNEC. Through the depiction of the genomic landscape and transcriptome profile, we compared the difference between CRNEC and CR neuroendocrine tumours (CRNETs). Immunohistochemistry (IHC) staining and immunofluorescence (IF) staining were performed to confirm the genetic alterations.
Looking for future studies?
Notify MeKey information
Age range
18 year–75 year
Sex eligibility
All sexes
Study type
Observational
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- tissues from colorectal neuroendocrine carcinomas
Exclusion criteria
- no
Treatment and study plan
Primary outcomes
-
overall survival
Time frame: 2010-2020
Secondary outcomes
-
Comprehensive genomic and expression panels (AmoyDx® Master Panel) for dna and rna detection
Time frame: 2020
Sponsors and collaborators
Lead sponsor
Zhejiang University
Other
Registry information
Important dates
- Study start
- 2011
- Primary completion
- 2021
- Study completion
- 2021
- First posted
- Feb 6, 2023
- Registry last updated
- Feb 12, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.